![]() ![]() This article draws on insights from a global survey conducted by McKinsey in June 2020 among 101 managers with recently launched drugs that had not reached their peak sales or drugs scheduled for launch between January and June 2020 that had been delayed. Companies chose to delay launches in 45 percent of cases, regulatory delays affected another 40 percent, and other external factors such as supply-chain problems accounted for the remaining 15 percent of delays. We found that between February and August 2020, all of these launches were disrupted through delays, lost revenues, or both. We analyzed 86 launches scheduled for 2018 onward with expected sales in excess of $300 million.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |